Tetra Bio-Pharma creates wholly-owned subsidiary ENJOUCA for branded medical cannabis products

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development, announced Tuesday the creation of a wholly-owned subsidiary called ENJOUCA. 

Jurisdictions differ greatly in terms of regulatory requirements surrounding medical cannabis, which means that in some territories, QIXLEEF can be commercialized as a medical cannabis product, the company said. 

As a result, Tetra said its strategy is to launch QIXLEEF under the trademark ENJOUCA as a medical cannabis product within those territories using its robust clinical package. 

READ: Tetra Bio-Pharma receives US FDA clearance on IND for QIXLEEF, setting the stage for clinical trial

ENJOUCA branded products will be distributed through existing medical cannabis channels.

For other jurisdictions, Tetra said that QIXLEEF will remain a prescription drug product and commercialized to the major global markets. As a prescription drug, QIXLEEF will be available by prescription only, through pharmacies.

Dania Scott, Tetra’s senior vice president for commercial strategy, will manage the ENJOUCA business unit, reporting to Chief Commercial Officer Steeve Néron.

“Tetra needed to strategically create distance between QIXLEEF and ENJOUCA,” said Dania Scott, ENJOUCA’s managing director, in a statement.

“These brands will command different commercial execution, from a supply, reimbursement, and promotional activity standpoint, due to different regulatory requirements. What is very positive is that we will be able to launch ENJOUCA in Canada during the second half of 2021. Patients and healthcare professionals will finally have a cannabinoid therapeutic option that is supported by strong evidence.”

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Story by ProactiveInvestors